Location: China
Total raised: $68.7M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.03.2026 | Seed | $68.7M | Mefine Cap... |
Mentions in press and media 4
| Date | Title | Description |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Excalipoint Therapeutics Raises $68.7M in Seed Funding | Excalipoint Therapeutics, a Shanghai, China-based biotechnology company developing T-cell engager (TCE) therapies for cancer and autoimmune diseases, raised $68.7M in Seed funding. Backers included HSG, Apricot Capital, Yuanbio Venture Capi... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| - | Excalipoint Therapetics | “Home—Excalipoint Therapeutics Inc” |